German biopharmaceutical company CureVac has hopes of getting approval from the European Union regarding the Covid-19 vaccine in the second quarter of this year.
In a statement, Chief Executive of CureVac, Franz-Werner Haas informed CNBC to near the finalizing of the recruitment for the vaccine’s Phase 3 clinical trial.
The vaccine approval will be swift given the urgent need for vaccination and accelerated regulatory process, he added. The expectations for approval might be toward the end of April or the beginning of May as per calculations. While the anticipated approval might take place in June, relying on the information.
In the awaiting process, the vaccine maker has already begun the production of the Covid-19 vaccine sans prior authorization. Upon kickstarting the trial, CureVac will await safety data followed by an analysis of results from the late-stage research. Additionally, the vaccines will have to prove their efficiency.
Over 455 million doses of the company’s vaccine based on its mRNA’s technology have been pre-ordered by the UK and EU as it awaits regulatory approval.
In efforts to combat the novel coronavirus, the company as well as others are trying to surpass the manufacturing struggles.
